TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of Others-
Division of General Internal Medicine
National Taiwan University Hospital Hsin-Chu Branch
Division of Hematology & Oncology
National Taiwan University Cancer Center
Division of Hematology & Oncology
更新時間：2023-09-19
蔡承宏TSAI, CHENG-HONG
- Principal Investigator
- Clinical Trial Experience (year) 12 years 9 個月
-
101627@ntuh.gov.tw
Publication
26Publications
1
Wang YH, Lin CC, Hsu CL, Hung SY, Yao CY, Lee SH, Tsai CH, Hou HA, Chou WC, Tien HF. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021 Feb;100(2):487-498. doi: 10.1007/s00277-020-04358-y. Epub 2020 Nov 23. PMID: 33225420; PMCID: PMC7817567.
2
Wang YH, Lin CC, Yao CY, Hsu CL, Hou HA, Tsai CH, Chou WC, Tien HF. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 2020 Feb 25;4(4):644-654. doi: 10.1182/bloodadvances.2019001185. PMID: 32078680; PMCID: PMC7042996.
3
Wang YW, Tsai CH, Lin CC, Tien FM, Chen YW, Lin HY, Yao M, Lin YC, Lin CT, Cheng CL, Tang JL, Chou WC, Hou HA, Tien HF. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020 Mar;99(3):501-511. doi: 10.1007/s00277-020-03911-z. Epub 2020 Jan 21. PMID: 31965269.
4
Wang WH, Lu MY, Tsai CH, Wang SC, Chou SW, Jou ST. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing. J Formos Med Assoc. 2021 Apr;120(4):1148-1152. doi: 10.1016/j.jfma.2020.08.034. Epub 2020 Sep 12. PMID: 32933826.
5
Wang YH, Lin CC, Lee SH, Tsai CH, Wu SJ, Hou HA, Huang TC, Kuo YY, Yao M, Chang KP, Lin CW, Lin YC, Tien FM, Chou WC, Tang JL, Tien HF. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer J. 2020 Oct 12;10(10):99
6
Wang WH, Lu MY, Tsai CH, Wang SC, Chou SW, Jou ST. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing. J Formos Med Assoc. 2020 Sep 12;S0929-6646(20)30408-3
7
Wang YW, Tsai CH, Lin CC, Tien FM, Chen YW, Lin HY, Yao M, Lin YC, Lin CT, Cheng CL, Tang JL, Chou WC, Hou HA, Tien HF. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020 Mar;99(3):501-511.
8
Wang YH, Lin CC, Yao CY, Hsu CL, Hou HA, Tsai CH, Chou WC, Tien HF. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 2020 Feb 25;4(4):644-654.
9
Tien FM, Tsai CH, Liu JH, Lin CT. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan. J Formos Med Assoc. 2019 Oct;118(10):1466-1470.
10
Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol. 2019 Jul;186(1):72-85
